News – Page 1129 – Endpoints News

Allergan scores an FDA OK for a new drug targeting night-time urination

9 years ago

More Senators accuse Marathon CEO Aronin of exploiting Duchenne MD patients as well as FDA’s orphan incentives

9 years ago

There has to be a better way to handle Duchenne drugs; Let's get to the bottom of the Juno debacle

9 years ago

Buyout buzz centers on a Novartis NASH deal for Genfit; Synthon joins the CD47 club

9 years ago

J&J may be late to the psoriasis drug market party, but it’s planning to make a splash with guselkumab

9 years ago

Sanofi steps up with a $645M deal to partner with AstraZeneca on a late-stage RSV antibody

9 years ago

Billionaire-backed Chi-Med declares PhIII success for pioneering cancer drug in China, seeking quick OK

9 years ago

IV formulation of Scynexis' lead antifungal gets sidelined by the FDA as regulators probe blood clots

9 years ago

Karyopharm flags a PhII overall survival failure for lead drug selinexor in acute myeloid leukemia

9 years ago

Bluebird’s star gene therapy patient still doing well after 15 months-plus; Takeda, Arix partner on biotech ...

9 years ago

OrbiMed doubling down on Asia biotech bets with $450M fund

9 years ago

PTC's ataluren flops in another PhIII and an analyst says it's clearly a dud; kill it

9 years ago

Roche shares spike as PhIII breast cancer combo with Perjeta scores a success, Puma takes a beating

9 years ago

Months after another lethal setback, Juno finally opts to kill lead CAR-T

9 years ago

Aurinia bounces back, shares soar on positive data for lupus drug

9 years ago

Grail grabs $900M-plus in Series B; Alnylam’s givosiran makes PRIME time

9 years ago

Celgene, Agios beat a short path to an FDA decision on AML drug

9 years ago

The top 10 orphan drugs in the late-stage pipeline

9 years ago

Icahn hires on gene therapy legend—and big biotech disruptor—Richard Mulligan as Bristol-Myers rumors simmer

9 years ago

Trump attacks “slow and burdensome” drug approval process, triggering a pitch from Amicus CEO

9 years ago

Lexicon bags FDA OK on lead drug for carcinoid syndrome, preps for a commercial launch

9 years ago

Merck KGaA, Pfizer win another quick FDA review for avelumab; WHO tries to spur more incentives for antibiotics R&D

9 years ago

Thumped by the FDA, Accera’s attempt to do a serious Alzheimer’s PhIII ends with a flop

9 years ago

Cempra slashes staff while shares tank (again) after a new series of setbacks for lead antibiotic

9 years ago

First page Previous page 1126 1127 112811291130 1131 1132 Next page Last page